Paritaprevir
| CAS No. | 1216941-48-8 | Cat. No. | BCP13942 |
| Name | Paritaprevir | ||
| Synonyms | ATB450; ABT-450; ABT 450;Veruprevir; | ||
| Formula | C40H43N7O7S | M. Wt | 765.88 |
| Description | Paritaprevir, also known as ABT-450 or Veruprevir, is an acylsulfonamide inhibitor of the NS3-4A serine protease manufactured by Abbott Laboratories that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1. Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3. | ||
| Pathways | Microbiology/Virology | ||
| Targets | HCV | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.